QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=A8AB09FA390A3AE4E0D1D6F38BF237B8;jsessionid=51586F57457820B19218871CCD1B1B0A;jsessionid=1378266A38B81A4711AC8DCC93F77B7F;jsessionid=73AC8971AD1AC6EB5D00E04011873BA7;jsessionid=F0B006071256602CB3F288DAD63A4DCE;jsessionid=084D8DE08BEC3C5A128D741EAF97F4D5;jsessionid=B3231D217D739F841D1CB1A505D89A39;jsessionid=5726B9A40D8763EE8B890DCCB23687FD;jsessionid=F3DF863B63DB4FD94EFC1F84A25390C8;jsessionid=2BF5395D766A54AADB4DFFB8EEE0CA3C (gene)

1. Ataxin-2 sequesters Raptor into aggregates and impairs cellular mTORC1 signaling.
2. The polyglutamine protein ATXN2: from its molecular functions to its involvement in disease.
3. Clinical features, disease progression, and nuclear imaging in ATXN2-related parkinsonism in a longi…
4. ATXN2 is a target of N-terminal proteolysis.
5. Abnormal open states patterns in the ATXN2 DNA sequence depends on the CAG repeats length.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=A8AB09FA390A3AE4E0D1D6F38BF237B8;jsessionid=51586F57457820B19218871CCD1B1B0A;jsessionid=1378266A38B81A4711AC8DCC93F77B7F;jsessionid=73AC8971AD1AC6EB5D00E04011873BA7;jsessionid=F0B006071256602CB3F288DAD63A4DCE;jsessionid=084D8DE08BEC3C5A128D741EAF97F4D5;jsessionid=B3231D217D739F841D1CB1A505D89A39;jsessionid=5726B9A40D8763EE8B890DCCB23687FD;jsessionid=F3DF863B63DB4FD94EFC1F84A25390C8;jsessionid=2BF5395D766A54AADB4DFFB8EEE0CA3C